Japanese biotech Nxera Pharma (TSE: 4565) has received a $15 million payment from Neurocrine Biosciences (Nasdaq: NBIX) after ...

Granta Park-based Nxera Pharma has received a $15million milestone payment after its partner, Neurocrine Biosciences, dosed ...

Nxera Pharma Tokyo, Japan and Cambridge, UK, 3 June 2025 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) today announces that its partner, Neurocrine Biosciences ...

Cambridge UK and Tokyo biopharma business Nxera Pharma has hauled in $15 million after partner Neurocrine Biosciences dosed the first patient in its Phase 3 registrational programme of NBI-1117568 ...

As Nxera Pharma proceeds into the “next era” implied by its name—following a rebrand from Sosei Group last year—the Japanese drugmaker is adding a new executive to help guide its growth plans.

(RTTNews) - Nxera Pharma Co., Ltd. announced that it has achieved a development milestone under its multi-target collaboration and license agreement with Eli Lilly and Co. (LLY) targeting diabetes ...

Nxera Pharma has announced a significant development milestone in its multi-target collaboration with Eli Lilly, marking a ...

Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) today announces that it has achieved a development milestone ...

In collaboration with Eli Lilly and Company (NYSE:LLY), a pharmaceutical company recognized globally for its innovative ...

Nxera previously announced the initiation of the Phase 3 registrational program of NBI-'568 by Neurocrine in May 2025. The ...